These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 36105402)

  • 21. LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma.
    Liu B; Chen Y; Yang J
    Oncotarget; 2017 Apr; 8(15):24275-24291. PubMed ID: 27903974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation.
    Quintanal-Villalonga A; Taniguchi H; Zhan YA; Hasan MM; Chavan SS; Meng F; Uddin F; Allaj V; Manoj P; Shah NS; Chan JM; Ciampricotti M; Chow A; Offin M; Ray-Kirton J; Egger JD; Bhanot UK; Linkov I; Asher M; Roehrl MH; Ventura K; Qiu J; de Stanchina E; Chang JC; Rekhtman N; Houck-Loomis B; Koche RP; Yu HA; Sen T; Rudin CM
    J Hematol Oncol; 2021 Oct; 14(1):170. PubMed ID: 34656143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High expression of PD-L1 mainly occurs in non-small cell lung cancer patients with squamous cell carcinoma or poor differentiation.
    Liu LU; Xie B; Zhu W; He Q; Zhou J; Liu S; Tao Y; Xiao D
    Oncol Res; 2023; 31(3):275-286. PubMed ID: 37305382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
    Meng F; Zhang L; Ren Y; Ma Q
    J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential applications of prognostic and immunological marker transmembrane serine proteinase 2 in prediction, prevention and personalized treatment of lung cancer.
    Mu B; Zhang R; Pu Y; Yao J; Hu X; Zhao C
    Eur J Cancer Prev; 2023 Jan; 32(1):65-68. PubMed ID: 35170548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Zengin T; Önal-Süzek T
    J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33672117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.
    Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L
    Mol Cancer; 2019 Jan; 18(1):7. PubMed ID: 30626401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vascular Invasion Predicts Recurrence in Stage IA2-IB Lung Adenocarcinoma but not Squamous Cell Carcinoma.
    Suaiti L; Sullivan TB; Rieger-Christ KM; Servais EL; Suzuki K; Burks EJ
    Clin Lung Cancer; 2023 May; 24(3):e126-e133. PubMed ID: 36631388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma.
    Li L; Liu YD; Zhan YT; Zhu YH; Li Y; Xie D; Guan XY
    Thorac Cancer; 2018 Jul; 9(7):775-784. PubMed ID: 29722145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Precise pathological classification of non-small cell lung adenocarcinoma and squamous carcinoma based on an integrated platform of targeted metabolome and lipidome.
    Cao P; Wu S; Guo W; Zhang Q; Gong W; Li Q; Zhang R; Dong X; Xu S; Liu Y; Shi S; Huang Y; Zhang Y
    Metabolomics; 2021 Nov; 17(11):98. PubMed ID: 34729658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Archaea Microbiome Dysregulated Genes and Pathways as Molecular Targets for Lung Adenocarcinoma and Squamous Cell Carcinoma.
    Uzelac M; Li Y; Chakladar J; Li WT; Ongkeko WM
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptome analysis of distinct long non-coding RNA transcriptional fingerprints in lung adenocarcinoma and squamous cell carcinoma.
    Wei Y; Zhang X
    Tumour Biol; 2016 Oct; ():. PubMed ID: 27797003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Shared network pattern of lung squamous carcinoma and adenocarcinoma illuminates therapeutic targets for non-small cell lung cancer.
    Li P; Kuang X; Zhang T; Ma L
    Front Surg; 2022; 9():958479. PubMed ID: 36263088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differentiated regulation of immune-response related genes between LUAD and LUSC subtypes of lung cancers.
    Chen M; Liu X; Du J; Wang XJ; Xia L
    Oncotarget; 2017 Jan; 8(1):133-144. PubMed ID: 27863400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
    Xu XL; Gong Y; Zhao DP
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telomere-associated genes and telomeric lncRNAs are biomarker candidates in lung squamous cell carcinoma (LUSC).
    Storti CB; de Oliveira RA; de Carvalho M; Hasimoto EN; Cataneo DC; Cataneo AJM; De Faveri J; Vasconcelos EJR; Dos Reis PP; Cano MIN
    Exp Mol Pathol; 2020 Feb; 112():104354. PubMed ID: 31837325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LDHA upregulation independently predicts poor survival in lung adenocarcinoma, but not in lung squamous cell carcinoma.
    Yu C; Hou L; Cui H; Zhang L; Tan X; Leng X; Li Y
    Future Oncol; 2018 Oct; 14(24):2483-2492. PubMed ID: 29756998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of four genes in exosomes as biomarkers for the identification of lung adenocarcinoma and lung squamous cell carcinoma.
    Cao B; Wang P; Gu L; Liu J
    Oncol Lett; 2021 Apr; 21(4):249. PubMed ID: 33664813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of Carbon-Bound Exogenous Compounds Impact Disease Pathophysiology in Lung Cancer Subtypes in Different Ways.
    Shen J; Sun N; Wang J; Zens P; Kunzke T; Buck A; Prade VM; Wang Q; Feuchtinger A; Hu R; Berezowska S; Walch A
    ACS Nano; 2023 Sep; 17(17):16396-16411. PubMed ID: 37639684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.